New Therapeutic Strategies in Heart Failure
Abstract
This is an exciting time for the field of pediatric heart failure. While historically there has been little improvement in overall outcomes (Kantor et al., 2010; Towbin et al., 2006), there is the recent suggestion that both short-term and long-term outcomes may be improving (Wittlieb-Weber et al., 2015; Singh et al., 2014; Alexander et al., 2013). There are likely multiple factors that have contributed to this including the evolution and focus on pediatric heart failure as a distinct specialty within pediatric cardiology, improved medical management, and improved options for mechanical circulatory support. Moreover, there are many new promising therapies that will hopefully further improve heart failure outcomes for children in the coming decades. This chapter will focus on several of these therapies including regenerative therapy, new medications for acute and chronic therapy that are beneficial for adult heart failure patients (e.g., valsartan/sacubitril, ivabradine, serelaxin), and the next generation of ventricular assist devices.
Publication Title
Heart Failure in the Child and Young Adult from Bench to Bedside
Recommended Citation
Rossano, J., Jefferies, J., & Dreyer, W. (2017). New Therapeutic Strategies in Heart Failure. Heart Failure in the Child and Young Adult from Bench to Bedside, 565-574. https://doi.org/10.1016/B978-0-12-802393-8.00044-2
